Folate Receptor alpha (FRα) Targeted Therapy: a Competitor Analysis

This competitive intelligence report Folate Receptor alpha (FRα) Targeted Therapy provides a competitor evaluation in the field of product and product candidates targeting Folate Receptor alpha as of July of 2025.

Folate receptor alpha (FRα) is a cell surface GPI-anchored protein overexpressed in several solid tumors with highest prevalence in ovarian cancer and lung adenocarcinoma but restricted expression in normal tissues. An antibody drug conjugate (ADC) with a microtubule inhibitor (MTI) payload recently received accelerated approval from the FDA for FRα-expressing platinum-resistant ovarian cancer. Thus, folate receptor alpha is a clinically validated target with commercial potential as evidenced by sales of more than US$ 500 mln in its second full year of commercialization after first approval in 2022. Furthermore, the FRα-targeted ADC was the main reason for an equity value of US$ 10 bln when the originator company Immunogen was acquired by Abbvie.

Folate receptor alpha holds great promise as a target for next generation improved drug candidates based on drug modalities known to enhance effector function and/or to broaden the therapeutic window. Among FRα-targeted drug modalities in use for next generation therapy candidates are mono- and bispecific ADCs with novel targeting moieties and linker/payload technologies as well as novel small molecule drug conjugates. Furthermore, next generation cell therapy modalities and radiopharmaceuticals are advancing in the pipeline.

This product consists of a competitor description and analysis in a tabular format provided as a pdf document which is sent by e-mail within one day, usually within one hour.

The pdf report includes a compilation of marketed and currently active projects in research and development of FRα-targeted product and product candidates.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis reports:
Competitor Analysis reports deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced with hyperlinks to the source of information.